Zevra Therapeutics, Inc. (ZVRA)
(Real Time Quote from BATS)
$4.87 USD
-0.02 (-0.41%)
Updated May 14, 2024 12:00 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Zevra Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 68 | 83 | 112 | 4 | 3 |
Receivables | 17 | 8 | 2 | 3 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 1 | 1 | 2 |
Total Current Assets | 87 | 93 | 115 | 8 | 7 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 20 | 15 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 74 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 10 | 1 | 0 | 0 | 1 |
Total Assets | 172 | 116 | 133 | 11 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 28 | 6 | 3 | 7 | 5 |
Current Portion Long-Term Debt | 38 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 5 | 1 | 0 | 0 |
Total Current Liabilities | 74 | 12 | 4 | 8 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 68 | 77 |
Long-Term Debt | 5 | 13 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 31 | 4 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 110 | 30 | 6 | 78 | 85 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 473 | 402 | 397 | 192 | 171 |
Retained Earnings | -400 | -309 | -267 | -258 | -246 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 11 | 8 | 3 | 0 | 0 |
Total Shareholder's Equity | 62 | 86 | 127 | -66 | -74 |
Total Liabilities & Shareholder's Equity | 172 | 116 | 133 | 11 | 11 |
Total Common Equity | 62 | 86 | 127 | -66 | -74 |
Shares Outstanding | 36.22 | 34.51 | 35.00 | 4.50 | 2.00 |
Book Value Per Share | 1.71 | 2.49 | 3.63 | -14.76 | -37.23 |
Fiscal Year End for Zevra Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 53 | 68 | 83 | 87 | 95 |
Receivables | 8 | 17 | 10 | 14 | 8 |
Notes Receivable | 0 | 0 | 42 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 1 |
Total Current Assets | 63 | 87 | 137 | 103 | 104 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 72 | 74 | 0 | 0 | 0 |
Deposits & Other Assets | 14 | 10 | 1 | 1 | 1 |
Total Assets | 151 | 172 | 139 | 106 | 107 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 28 | 13 | 11 | 10 |
Current Portion Long-Term Debt | 0 | 38 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 1 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 7 | 8 | 7 | 5 |
Total Current Liabilities | 30 | 74 | 22 | 18 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 43 | 5 | 44 | 13 | 13 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29 | 5 | 5 | 6 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 102 | 110 | 72 | 37 | 35 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 476 | 473 | 418 | 405 | 403 |
Retained Earnings | -416 | -400 | -339 | -325 | -320 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 11 | 11 | 11 | 11 | 11 |
Total Shareholder's Equity | 49 | 62 | 67 | 69 | 71 |
Total Liabilities & Shareholder's Equity | 151 | 172 | 139 | 106 | 107 |
Total Common Equity | 49 | 62 | 67 | 69 | 71 |
Shares Outstanding | 43.43 | 36.22 | 33.90 | 34.50 | 34.50 |
Book Value Per Share | 1.12 | 1.71 | 1.99 | 1.99 | 2.07 |